Mistry Pramod K,...,Petakov Milan S,...,(broj koautora 18) (2021) Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results, AMERICAN JOURNAL OF HEMATOLOGY, vol. 96, br. 9, str. 1156-1165 (Article) 

Mistry Pramod K,...,Petakov Milan S,...,(broj koautora 18) (2020) Individual patient responses to eliglustat in treatment-naive adults with Gaucher disease type 1: Final data from the phase 3 ENGAGE trial, MOLECULAR GENETICS AND METABOLISM, vol. 129, br. 2, str. S110-S111 (Meeting Abstract) 

Mistry Pramod K,...,Petakov Milan S,...,(broj koautora 26) (2019) Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1, BLOOD CELLS MOLECULES AND DISEASES, vol. 77, br. , str. 101-102 (Letter) 

Mistry Pramod K,...,Petakov Milan S,...,(broj koautora 26) (2018) Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1, BLOOD CELLS MOLECULES AND DISEASES, vol. 71, br. , str. 71-74 (Letter) 

Mistry Pramod K,...,Petakov Milan S,...,(broj koautora 18) (2017) Outcomes after 18 months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: The phase 3 ENGAGE trial, AMERICAN JOURNAL OF HEMATOLOGY, vol. 92, br. 11, str. 1170-1176 (Article) 

Mistry Pramod K,...,Petakov Milan S,...,(broj koautora 18) (2017) Long-term results of ENGAGE: a phase 3, randomized, double blind, placebo-controlled, multi center study investigating the efficacy and safety of eliglustat in adults with type 1 Gaucher disease, MOLECULAR GENETICS AND METABOLISM, vol. 120, br. 1-2, str. S97-S98 (Meeting Abstract) 

Mistry Pramod K,...,Petakov Milan S,...,(broj koautora 21) (2015) Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1 The ENGAGE Randomized Clinical Trial, JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 313, br. 7, str. 695-706 (Article) 

Mistry Pramod K,Lukina Elena,Ben Dridi Marie-Francoise,Amato Dominick J,Baris Hagit,Dasouki Majed,Ghosn Marwan,Mehta Atul,Packman Seymour,Pastores Gregory M,Petakov Milan S,Peterschmitt Judith M (2013) A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in patients with Gaucher disease type 1 (ENGAGE): Results after 9 months of treatment, MOLECULAR GENETICS AND METABOLISM, vol. 108, br. 2, str. S66-S67 (Meeting Abstract)